ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Alpha-PD1/IL2 Fusion Protein AWT020

Its studies are led by Anwita Biosciences.

Drug pageAlpha-PD1/IL2 Fusion Protein AWT020: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 1, since Oct 9, 20232 company-led studies, 2 open or runningNext primary completion: Jan 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Anwita Biosciences22 open or runningphase 1since Oct 9, 2023Oct 9, 2023Jan 2029phase 1 · NCT07822919

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 9, 2023First study: phase 1 study in Advanced CancerFirst studyNCT06092580 · 60 planned · Australia
  2. Sep 2, 2026Phase 1 study in Advanced Cancers (Solid Tumors)NCT07822919 · 96 planned · United States

Ahead

  1. Jan 2029Primary completion: phase 1 study in Advanced Cancers (Solid Tumors)NCT07822919

TargetBeta

PDCD1 →read by rule
“A bifunctional fusion protein comprised of a monoclonal antibody directed against the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) ”NCIt, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07822919Advanced Cancers (Solid Tumors) · United States1RecruitingJan 202996
NCT06092580Advanced Cancer · Australia1RecruitingJun 30, 202660

How it is read

Names in the registry

  • “AWT020”, 2 entries

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.